Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: Prospective randomised finnbladder-4 study

European Urology

Volumn 68, Issue 4, 2015, Pages 611-617

  Järvinen, Riikka ^a   Marttila, Timo ^b   Kaasinen, Eero ^c   Rintala, Erkki ^a   Aaltomaa, Sirpa ^d   Kallio, Jukka ^e   Liukkonen, Tapani ^f   Puolakka, Veli Matti ^g   Seppänen, Marjo ^h   Tuhkanen, Kari ^d   Vaarala, Markku ⁱ   Viitanen, Jouko ^j   Boström, Peter J ^k  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^c HYVINKÄÄ HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f MIKKELI CENTRAL HOSPITAL   (Finland)

^g SOUTH KARELIA CENTRAL HOSPITAL   (Finland)

^h SATAKUNTA CENTRAL HOSPITAL   (Finland)

ⁱ OULU UNIVERSITY HOSPITAL   (Finland)

^j NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^k TURKU UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

Bacillus Calmette Gu rin; Instillation therapy; Interferon 2b; Long term efficacy; Mitomycin C; Recurrent; Superficial bladder cancer

Indexed keywords

BCG VACCINE; MITOMYCIN; RECOMBINANT ALPHA2B INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG INSTILLATION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SURVIVAL TIME; TRANSURETHRAL RESECTION; CANCER GRADING; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FINLAND; INTRAVESICAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FINLAND; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84941807191     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.02.022     Document Type: Article

References (25)

1. M. Babjuk, M. Burger, R. Zigeuner, and et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013 Eur Urol 64 2013 639 653
2. S. Gudjonsson, L. Adell, F. Merdasa, and et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study Eur Urol 55 2009 773 780
3. T. Cai, G. Nesi, G. Tinacci, and et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guérin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study J Urol 180 2008 1101 1115
4. P. Shang, J. Kwong, Z. Wang, and et al. Intravesical bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer Cochrane Database Sys Rev 2011 CD006885
5. E. Kaasinen, E. Rintala, A.-K. Pere, and et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guérin or alternating monthly interferon-α2B and bacillus Calmette-Guérin for prophylaxis of recurrent papillary superficial bladder carcinoma J Urol 164 2000 47 52
6. E. Kaasinen, E. Rintala, P. Hellström, and et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma Eur Urol 42 2002 167 174
7. M. Botteman, C. Pashos, A. Redaelli, B. Laskin, and R. Hauser The health economics of bladder cancer. A comprehensive review of the published literature Pharmacoeconomics 21 2003 1315 1330
8. J. Fine, and R. Gray A proportional hazards model for the subdistribution of a competing risk JASA 94 1999 496 509
9. P. Rajala, E. Kaasinen, E. Rintala, and et al. Cytostatic effect of different strains of Bacillus Calmette-Guerin on human blader cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha Urol Res 20 1992 215 217
10. W. Oosterlinck, Z. Kirkali, R. Sylvester, and et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: Results of an EORTC Genito-Urinary Group randomized phase 2 trial (30993) Eur Urol 59 2011 438 446
11. E. Kaasinen, H. Wijkström, P.-U. Malmström, and et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study Eur Urol 43 2003 637 645
12. J. Witjes, T. Caris, N. Mungan, J. Debruyne, and P. Witjes Results of randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guérin versus mitomycin C alone in patients with superficial bladder cancer J Urol 160 1998 1668 1672
13. E. Solsona, R. Madero, V. Chantada, and et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial Eur Urol 67 2015 508 516
14. J. Oddens, M. Brausi, R. Sylvester, and et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance Eur Urol 63 2013 462 472
15. F. Joudi, B. Smith, and M. O'Donnell National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2b for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344 348
16. M. O'Donnell, J. Krohn, and W. DeWolf Salvage intravesical therapy with interferon α-2b plus low dose bacillus Calmette-Guérin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guérin alone previously failed J Urol 166 2001 1300 1305
17. S. Bazarbashi, M. Raja, A. El Sayed, and et al. Prospective phase II trial of alternating intravesical bacillus Calmette- Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results J Surg Oncol 74 2000 181 184
18. K. Nepple, A. Lightwood, H. Rosevear, M. O'Donnell, and D. Lamm Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer J Urol 184 2010 1915 1919
19. S. Bazarbashi, H. Soudy, M. Abdelsalam, and et al. Co-administration of intravesical bacillus Calmette-Guérin and interferon α-2b as first line in treating superficial transitional cell carcinoma of the urinary bladder BJU Int 108 2011 1115 1118
20. R. Järvinen, E. Kaasinen, A. Sankila, E. Rintala FinnBladder Group Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without CIS: a subgroup analysis of the prospective, randomized FinnBladder I study with a 20-year follow-up Eur Urol 56 2009 260 265
21. R. Järvinen, E. Kaasinen, E. Rintala, and T.F. Group Long-term results of mitomycin C versus alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder: a subgroup analysis of the prospective, randomized FinnBladder 2 study with a 17-year follow-up Scand J Urol Nephrol 46 2012 411 417
22. P.-U. Malmström, H. Wijkström, C. Lundholm, and et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma J Urol 161 1999 1124 1127
23. D. Lamm, B. Blumenstein, E. Crawford, and et al. Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder Urol Oncol 1 1995 119 126
24. A. Böhle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Guerin versus mitomycin-C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
25. P. Rajala, E. Kaasinen, M. Raitanen, T. Liukkonen, E. Rintala FinnBladder Group Perioperative single dose instillation of epirubicin or interferon-α after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - FinnBladder III long-term results J Urol 168 2002 981 985